

2026 Q3 Results

Asymchem Laboratories (Tianjin) Co., Ltd.

002821.SZ/6821.HK

Disclaimer

This document is not for public dissemination and the information contained herein is for the exclusive use of the persons to whom it is addressed and their advisers in connection with Asymchem Laboratories (Tianjin) Co., Ltd. (the "**Company**", together with its subsidiaries, hereinafter referred to as the "**Group**"). It is being made available by the Company to a limited number of recipients. The contents of this document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and whoever comes into possession of this document should inform themselves about, and observe such restrictions. Any failure to comply with this restriction may constitute a violation of the United States, Canadian, PRC or Japanese securities laws or the laws of any such other jurisdictions. By accepting this document, you agree to be bound by the foregoing limitations.

Forward-Looking Statement

This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our clients' intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this presentation is as of the date of this presentation and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.

All financials disclosed in this document are presented in accordance with International Financial Reporting Standards ("**IFRS**"**s**) except for those specifically noted otherwise.

Use of Adjusted Financial Measures

We have provided adjusted net profit attributable to shareholders of the Company and adjusted net profit margin attributable to shareholders of the Company as additional financial measures, which are not required by, or presented in accordance with, the IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our business. However, the presentation of these non- IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS.

2026 Q1-Q3 Performance

5,395

Revenue (RMB mm)

+16.5%

@CER[2]: +20.0%

41.5%

Gross Profit Margin

@CER: +1.0pts[3]

852

Net Profit Attributable to Shareholders of the Listed Company (RMB mm)

+6.5%

1,074

Adjusted Net Profit Attributable to Shareholders of the Listed Company (RMB mm)

+21.8%

Small Molecule CDMO Business

Revenue	Gross Profit Margin
RMB3,465mm	47.5%
+3.6%	+0.7pts
@CER: +7.4%	@CER: +2.6pts

Emerging Business

Revenue	Gross Profit Margin
RMB1,923mm	30.9%
+50.2%	+0.6pts
@CER: +52.7%	@CER: +1.7pts


The Company achieved revenue of **RMB1,788 mm** for Q3, representing a *yoy*[4] increase of **24.0%**, or **28.3%** @CER.
Driven by a focus on improving operational efficiency to effectively boost business profitability and competitiveness,
the net profit attributable to shareholders of the listed company increased by **81.5%** *yoy* in Q3, and the adjusted net profit increased by **49.6%** *yoy*.

Based on the backlog, the delivery scale in Q4 is expected to increase significantly as compared with the Reporting Period,
and the Company expects its operating revenue for the full year of 2026 to increase by **19% to 22%**


1、All financials disclosed in this document are presented in accordance with IFRS except for those specifically noted otherwise
2、@CER: @ a constant exchange rate
3、PTS: percentage points
4、yoy: year on year

Performance by Customer Type

Revenue From Large Pharma
(Excluded Large Orders in 2023)



Revenue From Small-to-Mid Pharma




Based on region, revenue from customers in overseas markets amounted to **RMB3,623 mm**, demonstrating a *yoy* increase of **11.6%** on a constant currency basis, while revenue from customers in the domestic market amounted to **RMB1,772 mm**, reflecting a *yoy* increase of **42.8%**

Adjusted Net Profit

RMB mm	2026 Q1-Q3	2025 Q1-Q3
Net Profit Attributable to Shareholders of the Listed Company	852	800
Add:		
Amortization Expenses of Share-based Compensation	55	46
Gain or Loss on Exchange Rate Fluctuations	238	50
Realised and unrealised losses on equity instrument investments	(71)	(15)
Adjusted Net Profit Attributable to Shareholders of the Listed Company	**1,074**	**881**
Adjusted Net Profit Margin Attributable to Shareholders of the Listed Company	**19.9%**	**19.0%**


Adjusted Net Profit Attributable to Shareholders of the Listed Company




In 2026, with improving operating efficiency as its core focus, the Company shifted from a “cost reduction and efficiency enhancement” approach to a “cost control and efficiency improvement” approach, to materially enhance business profitability and competitiveness. The growth in net profit lagged behind that of revenue, primarily attributable to the impact of exchange rate fluctuations

2026 Q1-Q3 Expenses


Selling and Distribution Expenses as % of Total Revenue




Administrative Expenses* as % of Total Revenue



R&D Expenses as % of Total Revenue




Finance Costs* as % of Total Revenue




*Due to the disparities between Chinese Accounting Standards (“CAS”) and International Financial Reporting Standards (“IFRS”), there exist variations in the treatment of administrative expenses and finance costs. Consequently, under IFRS, these expenses differ from those recognized under CAS. To accurately represent the concept of “net finance costs,” we have chosen to utilize finance costs as per CAS. This entails including exchange gains, bank interest income, bank charges, and other expenses/gains derived from financing activities.

Capital Expenditure



Outlook



The CDMO industry has shown a positive trend. After the Company returned the growth trajectory in 2025, orders will continue to grow while operation will remain favorable. The Company expects its operating performance in 2026 to show an accelerated growth trend with estimated revenue growth of 19-22%


In 2026, the Company will vigorously promote the development of emerging businesses such as chemical macromolecules and biological macromolecules CDMO businesses, firmly seizing market opportunities to continuously generate incremental contributions in these areas. Meanwhile, it will promote the steady development of small molecule business, laying a solid foundation for sustained growth in performance

Focusing on improving operational efficiency, the strategy will shift from cost reduction and efficiency enhancement to cost control and efficiency improvement, effectively increasing profit margins and business competitiveness

Driven by the Company's robust order pipeline and evolving customer requirements, the Company will further accelerate its capacity expansion. For 2026, Capex[1] is projected to be rise from the original budget of RMB2.1 billion set at the beginning of the year to RMB2.6 ~ RMB2.8 billion

1、Capex：Capital expenditure

Appendix



ASYMCHEM

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

RMB mm

	2026 Q1-Q3	2025 Q1-Q3
Revenue	**5,395**	**4,630**
Cost of sales	**(3,153)**	**(2,675)**
Gross profit	**2,242**	**1,955**
Other income and gains	207	266
Selling and distribution expenses	(172)	(150)
Administrative expenses	(699)	(609)
Research and development expenses	(356)	(433)
Net impairment losses on financial and contract assets	(8)	(36)
Other expenses	(351)	(77)
Finance costs	(11)	(9)
Share of profit of associates	95	3
Profit before tax	**947**	**910**
Income tax expense	(104)	(118)
Profit for the period	**843**	**792**
Attributable to:		
Owners of the parent	**852**	**800**
Non-controlling interests	(9)	**(8)**

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

RMB mm

	2026 Q3	2025
Non-current assets		
Property, plant and equipment	7,159	6,442
Right-of-use assets	713	669
Goodwill	146	146
Other intangible assets	23	25
Deferred tax assets	300	276
Investments in associates	626	573
Prepayments, other receivables and other assets	676	446
Financial assets at fair value through profit or loss	188	194
Total non-current assets	**9,831**	**8,771**
Current assets		
Inventories	2,430	1,471
Trade receivables	2,148	1,977
Contract assets	95	83
Prepayments, other receivables and other assets	476	523
Tax recoverable	10	14
Financial assets at fair value through profit or loss	2,461	1,117
Cash and bank balances	4,183	6,321
Total current assets	**11,803**	**11,506**
Total assets	**21,634**	**20,277**

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
(continued)

RMB mm

	2026 Q3	2025
Current liabilities		
Trade payables	727	584
Other payables and accruals	1,679	1,247
Financial liabilities at fair value through profit or loss	11	10
Interest-bearing bank and other borrowings	80	-
Lease liabilities	56	53
Tax payable	69	69
Amounts due to related parties	3	5
Total current liabilities	**2,625**	**1,968**
Non-current liabilities		
Interest-bearing bank borrowings	320	-
Deferred income	326	295
Lease liabilities	234	256
Deferred tax liabilities	140	112
Other non-current liabilities	178	-
Total non-current liabilities	**1,198**	**663**
Equity		
Equity attributable to owners of the parent share capital	375	361
Treasury shares	(1,146)	(838)
Reserves	18,579	18,113
Non-controlling interests	3	11
Total equity	**17,811**	**17,646**

Thanks!



ASYMCHEM